Based on this result, we found that knockdown of GPX4 combined with PD-L1 inhibitor therapy can improve immunotherapy efficacy in gastric cancer (Figure 12H), suggesting a new therapeutic strategy for this disease. This evidence concerns the gene GPX4 and gastric cancer.